Alliance A021501的放射治疗质量保证分析:术前mFOLFIRINOX或mFOLFIRINOX联合大分割放射治疗可交界可切除胰腺腺癌
Alliance A021501是首个评估新辅助化疗后立体定向体部放疗(SBRT)用于可交界可切除胰腺导管腺癌(PDAC)的随机试验,本事后研究分析了放疗质量。39例可评估患者中82.1%接受SBRT、17.9%接受大分割放疗,5例(13%)治疗前需修改计划;事后评审中59.0%病例轮廓或计划覆盖欠佳,12例(30.8%)评分为2、11例(28.2%)评分为3。不同治疗技术或事后病例评分间未见失败模式或手术结局的明显差异。
要点
- 39例可评估患者中32例(82.1%)接受SBRT、7例(17.9%)接受大分割放疗,5例(13%)治疗前需修改。
- 事后评审中23例(59.0%)轮廓或计划覆盖欠佳,12例(30.8%)评分为2、11例(28.2%)评分为3。
- 不同治疗技术或事后病例评分间未见失败模式或手术结局的明显差异。
核心结论
- 尽管实施了严格的质量保证,试验中仍在模拟定位、轮廓勾画、计划覆盖和剂量方面遇到差异;临床结局似乎未受影响,但该分析结果可用于指导后续PDAC SBRT试验设计和QA要求。
研究设计与样本
- Alliance A021501是首个评估新辅助化疗后SBRT用于可交界可切除PDAC的随机试验,本事后研究分析放疗质量。
- 计划SBRT(6.6 Gy×5),若无法满足SBRT规格则允许大分割放疗(5 Gy×5)。
- 要求通过美国国家癌症研究所资助的影像与放射肿瘤学核心(IROC)进行机构认证,并强制进行严格放疗质量保证(RT QA),包括放疗科医生治疗前审查。
- 事后RT QA分析由3名放疗科医生评审轮廓和计划,按充分性评分1(无偏差)、2(轻微偏差)、3(可能有临床意义的重大偏差)。
- 40例患者注册接受放疗(1例计划但未治疗),来自27个中心(18个学术中心、9个社区中心);23个中心具备移动肺/肝靶区认证,4个中心仅具备静态头颈认证。
主要发现
- 39例可评估患者中32例(82.1%)接受SBRT,7例(17.9%)接受大分割放疗。
- 5例(13%)在治疗前需要修改。
- 事后评审中23例(59.0%)轮廓或计划覆盖欠佳,12例(30.8%)评分为2,11例(28.2%)评分为3。
- 基于治疗技术或事后病例评分,失败模式或手术结局未见明显差异。
- 与治疗中成像相关的细节未记录。
局限性
- 与治疗中成像相关的细节未记录。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Alliance A021501 is the first randomized trial to evaluate stereotactic body radiation therapy (SBRT) for borderline resectable pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant chemotherapy. In this post hoc study, we reviewed the quality of radiation therapy (RT) delivered. METHODS AND MATERIALS: SBRT (6.6 Gy × 5) was intended but hypofractionated RT (5 Gy × 5) was permitted if SBRT specifications could not be met. Institutional credentialing through the National Cancer Institute-funded Imaging and Radiation Oncology Core (IROC) was required. Rigorous RT quality assurance (RT QA) was mandated, including pretreatment review by a radiation oncologist. Revisions were required for unacceptable deviations. Additionally, we performed a post hoc RT QA analysis in which contours and plans were reviewed by 3 radiation oncologists and assigned a score (1, 2, or 3) based on adequacy. A score of 1 indicated no deviation, 2 indicated minor deviation, and 3 indicated a major deviation that could be clinically significant. Clinical outcomes were compared by treatment modality and by case score. RESULTS: Forty patients were registered to receive RT (1 planned but not treated) at 27 centers (18 academic and 9 community). Twenty-three centers were appropriately credentialed for moving lung/liver targets and 4 for static head and neck only. Thirty-two of 39 patients (82.1%) were treated with SBRT and 7 (17.9%) with hypofractionated RT. Five cases (13%) required revision before treatment. On post hoc review, 23 patients (59.0%) were noted to have suboptimal contours or plan coverage, 12 (30.8%) were scored a 2, and 11 (28.2%) were scored a 3. There were no apparent differences in failure patterns or surgical outcomes based on treatment technique or post hoc case score. Details related to on-treatment imaging were not recorded. CONCLUSIONS: Despite rigorous QA, we encountered variability in simulation, contouring, plan coverage, and dose on trial. Although clinical outcomes did not appear to have been affected, findings from this analysis serve to inform subsequent PDAC SBRT trial designs and QA requirements.
引用
- Tchelebi LT, Segovia D, Smith K, et al. Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas. Int J Radiat Oncol Biol Phys. 2024. PMID: 38492812. doi:10.1016/j.ijrobp.2024.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。